FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to methods of treating follicular lymphoma and lymphoma. Method of treating follicular lymphoma involves administering to a subject in need thereof a therapeutically effective dose of compound 44
Compound 44
or a pharmaceutically acceptable salt thereof, a therapeutically effective dose of lenalidomide and a therapeutically effective dose of rituximab; wherein follicular lymphoma is resistant or refractory to at least one previous therapy; and wherein compound 44, said lenalidomide and said rituximab are administered simultaneously or sequentially. Method of treating cancer, where the cancer is lymphoma, involves administering to a subject in need thereof a therapeutically effective dose of compound 44 or a pharmaceutically acceptable salt thereof, a therapeutically effective dose of rituximab and a therapeutically effective dose of lenalidomide; wherein cancer is resistant or refractory to at least one previous therapy; and wherein compound 44, and said rituximab, and said lenalidomide are administered simultaneously or sequentially.
EFFECT: methods described above using compound 44, lenalidomide and rituximab have a synergistic effect in treating lymphoma and follicular lymphoma.
14 cl, 10 dwg, 4 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL PROTEIN COMPOSITIONS OBTAINED BY RATIONAL DESIGN | 2019 |
|
RU2816719C2 |
| COMPOSITION FOR ANTICANCER TREATMENT CONTAINING NK-CELLS AND FUSION PROTEIN WHICH CONTAINS IL-2 PROTEIN AND CD80 PROTEIN | 2020 |
|
RU2832136C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATING MALIGNANT TUMOUR CONTAINING FUSION PROTEIN CONTAINING IL-2 PROTEIN AND CD80 PROTEIN, AND IMMUNE CONTROL POINT INHIBITOR | 2020 |
|
RU2828377C1 |
| FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN AND ITS USE | 2019 |
|
RU2811541C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| INTERLEUKIN-18 OPTIONS AND METHODS FOR THEIR USE | 2018 |
|
RU2797536C2 |
| HERPES VIRUS WITH A MODIFIED SPECTRUM OF TARGETS CONTAINING HYBRID GLYCOPROTEIN H | 2016 |
|
RU2732120C2 |
| HYBRID PROTEINS OF sPD-1-Fc VARIANT | 2019 |
|
RU2785993C2 |
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
